Effective and evidence-based responses to the increased availability and use of synthetic drugs and stimulants in Europe
Issued by European Commission · via EU Funding & Tenders Portal
- Published
- 26 Sept 2026
- Closes
- 4 Nov 2027
- Reference
- HORIZON-CL3-2027-01-FCT-05
- Location
- Global / multi-country
- Sector
- Healthcare & Pharma
Details
Expected Outcome:
Project results are expected to contribute to all of the following expected outcomes:
- Evidence base is improved for effective prevention, treatment and harm reduction of synthetic drugs and stimulants in Europe;
- Relevant European security practitioners, notably Police Authorities, Civil Society Organisations and Non-Governmental Organisations, are equipped with skills, tools and technology aimed at reducing the violence and offences associated with use and marketing of these substances, as well as at combatting drug trafficking from its origin to destination (i.e., through the entire supply chain);
- Increased understanding of relevant European security practitioners and policymakers regarding the influence of external drivers of change of societal, technological, legal, economic and ethical nature to the availability and use of different types of synthetic drugs and drug markets.
Scope:
This topic asks for proposals that seek to develop effective and evidence-based responses to the growing prevalence of synthetic drugs and stimulants, such as cocaine and crack cocaine, within the EU. As these substances increasingly influence the drug landscape, the urgent need for enhanced understanding and strategies in their prevention, treatment, and harm reduction has never been clearer. Amongst other, there is also a lack of pharmacological data for the emerging drugs, needed to do proper risk assessments and interventions of these drugs in Europe. Key focus areas include:
- Evidence-based approaches, strengthening the evidence base to inform effective prevention strategies, treatment modalities, and harm reduction practices targeted at synthetic drugs and stimulants. This includes identifying best practices in current interventions and evaluating their efficacy.
- Reducing violence and offending exploring strategies to mitigate the violence and criminal behaviour associated with the use and marketing of synthetic drugs. This involves understanding the socio-economic and cultural factors, including the gender, age, or other social factors, that contribute to these phenomena and proposing targeted interventions.
- Improving technologies and tools to combat drug trafficking from its origin to destination (i.e., through the entire supply chain).
- External drivers of change, analysing the impact of geopolitical situations, legal frameworks, and societal factors on the availability and consumption of various drugs, and addressing how international crises affect organised crime and drug markets in the EU. This includes investigating the repercussions of global developments on local drug dynamics and identifying adaptive response strategies.
In light of the underdeveloped evidence base surrounding synthetic drugs, proposals should aim to foster collaboration among researchers, policymakers, and security practitioners to create a comprehensive and effective response to this pressing issue in Europe, previous research, including but not limited to research by other Framework Programmes’ projects. Coordination among the successful proposals from this topic should be envisaged to avoid duplication and to exploit complementarities as well as opportunities for increased impact. To ensure the active involvement of and timely feedback from relevant security practitioners, proposals should plan a mid-term deliverable consisting in the assessment of the project’s mid-term outcomes, performed by the practitioners involved in the project. Activities proposed within this topic should address, in a balanced way, both technological and societal dimensions of the issue under consideration. The proposals funded under this topic are expected to engage with the Europol Innovation Lab during the lifetime of the project, including validating the outcomes, with the aim of facilitating future uptake of innovations for the law enforcement community. Similarly, the proposals funded under this topic are expected to engage with the EU Drugs Agency during the lifetime of the project, including validating the outcomes. Finally, proposals are expected to address all applicable considerations expressed in the Introduction of the Fighting Crime and Terrorism Destination. null Activities are expected to achieve TRL 6-8 by the end of the project – see General Annex B.
Submissions open on 05 May 2027.
Part of call HORIZON-CL3-2027-01
Type of action: HORIZON Innovation Actions
Programme period: 2021 - 2027
Priorities: SocietalEngagement, AI, DigitalAgenda
"> General conditions
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
DELETE ME Please add hyperlinks as embedded links where needed (underscored text). Send the call document through the document publication form to receive the hyperlink within 2 business days max. DELETE ME
2. Eligible Countries
described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide .
3. Other Eligible Conditions
The following additional eligibility criteria apply: This topic requires the active involvement, as beneficiaries, of at least 3 Police Authorities[[In the context of this Destination, ‘Police Authorities’ means public authorities explicitly designated by national law, or other entities legally mandated by the competent national authority, for the prevention, detection and/or investigation of terrorist offences or other criminal offences, specifically excluding police academies, forensic institutes, training facilities as well as border and customs authorities.]] and at least 2 Civil Society Organisations (or Non-Gove
Context for bidders
We hold 219 notices from European Commission, going back to August 2026 — 219 of them still open. They buy mostly in Water & Environment, Healthcare & Pharma and IT & Telecom. There are 31 open Healthcare & Pharma tenders in Global / multi-country. This one closes in 404 days.
More from this buyer
- European Partnership for Pandemic Preparedness (Phase 2)· closes 13 Apr
- Portable and versatile Point-of-care diagnostics· closes 13 Apr
- Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies· closes 21 Sept
- Hydrogen cities· closes 7 Oct
- ERA Fellowships· closes 8 Sept
Similar Healthcare & Pharma tenders
- Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes· closes 21 Sept
- Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research· closes 21 Sept
- European Partnership for Pandemic Preparedness (Phase 2)· closes 13 Apr
- Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases· closes 13 Apr
- Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies· closes 21 Sept
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- 北京华信医院(清华大学第一附属医院)危重新生儿救治中心能力提升(信息系统)项目公开招标公告北京华信医院 · China
- 北京华信医院(清华大学第一附属医院)医学影像系统项目公开招标公告北京华信医院 · China
- 华中科技大学同济医学院附属同济医院蜂巢式细胞培养系统采购项目公开招标公告华中科技大学同济医学院附属同济医院 · China
- 华中科技大学同济医学院附属同济医院全自动免疫组化及原位杂交染色平台采购项目公开招标公告华中科技大学同济医学院附属同济医院 · China
- 华中科技大学同济医学院附属同济医院高效液相色谱仪采购项目公开招标公告华中科技大学同济医学院附属同济医院 · China
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →